News

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with ...
Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.
Andrew Evens, DO, MBA, MSc, discusses a modern way of stratifying risk in patients with early-stage Hodgkin lymphoma.
Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...
Blood cancer, which originates from irregular blood cell generation within the bone marrow, represents a serious health ...
TP53 mutation is a critical predictor of early disease progression and poor prognosis in mantle cell lymphoma (MCL). Optimal treatment for these patients remains unclear. This systematic review and ...
Volumetric PET biomarkers may help predict risk of toxicity from CAR T-cell therapy in patients with large B-cell lymphoma, ...
Waldenstrom Macroglobulinemia sees growing innovation as next-gen BTK inhibitors and novel therapies aim to overcome resistance and reshape treatment pathways. BTK inhibitors laid the groundwork, but ...
Antibody–Drug Conjugates for the Treatment of B-cell Non–Hodgkin's Lymphoma and Leukemia Yu-Waye Chu; Andrew Polson Disclosures Future Oncol. 2013;9 (3):355-368.
Large B-cell lymphomas (LBCL), composed predominantly of diffuse large B-cell lymphoma (DLBCL), are the most common type of non-Hodgkin lymphoma (NHL) that affect B-cell lymphocytes, a type of ...
ICI have shown impressive activity for treatment of cHL and primary mediastinal large B cell lymphoma, but efficacy of ICI for most other types of non-Hodgkin lymphoma has been limited.